Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: A case report

European Journal of Clinical Pharmacology

Volumn 58, Issue 9, 2002, Pages 593-595

  Bocci, G ^a,b   Danesi, R ^b   Allegrini, G ^c   Innocenti, F ^b   Di Paolo, A ^b   Falcone, A ^c   Conte, P F ^d   Del Tacca, M ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF PISA   (Italy)

^c Division of Medical Oncology   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

5 Fluoro 5,6 dihydrouracil; 5 Fluorouracil; Case report; Dihydropyrimidinedehydrogenase; Pharmacokinetics; Toxicity

Indexed keywords

DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; URACIL; 5-FLUORODIHYDROURACIL; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE;

ACUTE TOXICITY; ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DERMATITIS; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MONONUCLEAR CELL; NEUTROPENIA; PRIORITY JOURNAL; RECTUM CARCINOMA; STOMATITIS; VOMITING; ALOPECIA; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; FEVER; MIDDLE AGED;

ALOPECIA; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; DIARRHEA; DRUG ERUPTIONS; FEMALE; FEVER; FLUOROURACIL; HUMANS; MIDDLE AGED; NEUTROPENIA; STOMATITIS; VOMITING;

EID: 0036460047     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0534-6     Document Type: Article

References (15)

1. Bocci G, Danesi R, Di Paolo A, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M (2000) Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 6:3032-3037
2. Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del Tacca M (2001) Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12:1301-1306
3. Diasio RB, Johnson MR (2000) The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61:199-203
4. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902
5. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17:1105-1112
6. Grem JL (2000) 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299-313
7. Hayashi K, Kidouchi K, Sumi S, Mizokami M, Orito E, Kumada K, Ueda R, Wada Y (1996) Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydro-pyrimidinuria. Clin Cancer Res 2:1937-1941
8. Johnson MR, Diasio RB (2001) Importance of dihydropyrim-idine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151-157
9. Milano G, Etienne MC (1996) Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: Theory and limits. Ther Drug Monit 18:335-340
10. Milano G, McLeod HL (2000) Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 36:37-42
11. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydro-genase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 7:2832-2839
12. Rowland M, Tozer TN (1995) Clinical Pharmacokinetics. Concepts and Applications, 3rd Edn. Lippincot Williams & Wilkins, Philadelphia
13. Stephan F, Etienne MC, Wallays C, Milano G, Clergue F (1995) Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 99: 685-688
14. Van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, Van Gennip AH (2001) Lethal outcome of a patient with a complete dihy-dropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:1149-1153
15. Volk J, Reinke F, Van Kuilenburg AB, Van Gennip AH, Schlichting C, Ganser A, Scho3ski P (2001) Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-defi-cient patient with metastatic colon cancer. Ann Oncol 12: 569-571